Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + Chemotherapy in HER2-low, HR+ Breast Cancer
NCT05165225Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2021
- Primary completion
- Sep 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Started Jul 2021; status: active, not recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05165225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05165225.